Wednesday, December 3, 2008

Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease

Wyeth Pharmaceuticals, a division of Wyeth , announced today that it has submitted a marketing authorization application to the European Medicines Agency for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children. Wyeth is seeking an indication for the prevention of pneumococcal disease (PD) caused by the 13 serotypes included in the investigational vaccine in infants and children from two months to five years of age.

The details can be read here.

No comments: